Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
11/30/2014
11/30/2013
11/30/2012
11/30/2011
11/30/2010
Revenus
0
0
0
0
0
0
Croissance des revenus (H/H)
--
--
--
--
--
--
Coût des ventes
0
--
--
--
--
--
Bénéfice brut
0
--
--
--
--
--
Vente, Général et Administration
0
0
1
1
1
0
Recherche et développement
0
0
0
0
0
0
Frais d'exploitation
0
0
1
1
2
1
Autres revenus (charges) non opérationnels
--
--
--
0
0
0
Bénéfice avant impôts
0
0
-1
-1
-1
-1
Charge d'impôt sur le revenu
--
--
0
0
0
0
Bénéfice net
0
0
-1
-1
-1
-1
Croissance du bénéfice net
--
-100%
0%
0%
0%
--
Actions en circulation (diluées)
5,000.94
3,726.16
1,915.73
1,035.17
692.92
379.78
Variation des actions (H-H)
-1%
95%
85%
49%
82%
103%
EPS (dilué)
0
0
0
0
0
0
Croissance du EPS
--
-83%
-50%
-54%
-24%
-28.99%
Flux de trésorerie libre
0
-1
-1
0
-1
0
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
0%
--
--
--
--
--
Marge opérationnelle
0%
0%
0%
0%
0%
0%
Marge bénéficiaire
0%
0%
0%
0%
0%
0%
Marge du flux de trésorerie libre
0%
0%
0%
0%
0%
0%
EBITDA
0
--
--
-1
-2
-1
Marge EBITDA
0%
--
--
0%
0%
0%
D&A pour le résultat opérationnel
0
--
--
0
0
0
EBIT
0
0
-1
-1
-2
-1
Marge EBIT
0%
0%
0%
0%
0%
0%
Taux d'imposition effectif
--
--
0%
0%
0%
0%
Follow-Up Questions
Multicell Technologies Inc의 주요 재무제표는 무엇인가요?
MCET의 주요 재무 비율은 무엇인가요?
Multicell Technologies Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Multicell Technologies Inc은 수익성이 있나요?
Multicell Technologies Inc에 부채가 있나요?
Multicell Technologies Inc의 발행 주식은 몇 주인가요?
Statistiques clés
Clôture préc.
$0
Prix d'ouverture
$0
Plage de la journée
$0 - $0
Plage de 52 semaines
$0 - $0
Volume
20.0K
Volume moyen
0
BPA (TTM)
-0.00
Rendement en dividend
--
Capitalisation boursière
$5.0K
Qu’est-ce que MCET ?
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. The company is headquartered in Woonsocket, Rhode Island. The firm and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The firm's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.